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FGR Fetal growth restriction
GlyT Glycogen trophoblast
ICM Inner cell mass
Jz Junctional zone
Lz Labyrinth zone
PAS Periodic acid Schiff
PE Preeclampsia
P-TGC Parietal Trophoblast Giant Cell (also P-)
S-TGC Sinusoidal Trophoblast Giant Cell (also S-)
SpA-TGC Spiral Artery-associated Trophoblast Giant Cell (also SpA-)
SpT Spongiotrophoblast
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Abstract
The placenta performs a range of crucial functions that support fetal growth during 
pregnancy, including facilitating the supply of nutrients and gases to the fetus, removal of 
waste products from the fetus, and the endocrine modulation of maternal physiology. The 
placenta also stores glucose in the form of glycogen, the function of which remains unknown. 
Aberrant placental glycogen storage in humans is associated with maternal diabetes during 
pregnancy and pre-eclampsia, thus linking placental glycogen storage and metabolism to 
pathological pregnancies. To understand the role of placental glycogen in normal and 
complicated pregnancies, we must turn to animal models. Over 40 targeted mutations in mice 
demonstrate defects in placental cells that store glycogen and suggest that placental glycogen 
represents a source of readily mobilised glucose required during periods of high fetal demand. 
However, direct functional evidence is currently lacking. Here, we evaluate these genetic 
mouse models with placental phenotypes that implicate glycogen trophoblast cell 
differentiation and function to illuminate the common molecular pathways that emerge and 
to better understand the relationship between placental glycogen and fetal growth. We 
highlight current limitations to exploring key questions regarding placental glycogen storage 
and metabolism and define how to experimentally overcome these constraints.
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Introduction
The placenta is a unique organ that exists only during pregnancy to perform a diverse range 
of functions that collectively support optimal fetal growth whilst maintaining maternal well-
being. Arguably, the principal role of the placenta is to mediate the supply of oxygen and 
nutrients from the mother to fetus (Burton and Fowden, 2015). The placenta also removes 
waste products from the fetal circulation and forms a physical barrier that affords some 
protection against certain pathogens and toxins (Gude et al., 2004). Furthermore, the 
placenta also synthesises and secretes hormones into the mother’s blood to adapt maternal 
physiology and behaviour, ultimately to ensure that the pregnancy is sustained, and fetal 
growth supported (Napso et al., 2018). In addition to facilitating glucose transport, the 
placenta metabolises glucose for its own use and stores it in the form of the multi-branched 
polysaccharide glycogen. The purpose of placental glycogen stores in normal pregnancy 
remains unclear. The most widely accepted theory is that placental glycogen stores ensure 
that fetal glucose supply is maintained at times of maximal demand, such as during late 
gestation (Coan et al., 2006, Barash and Shafrir, 1990). However, direct experimental 
evidence to support such a function is currently lacking.
Placental glycogen in humans 
Despite the earliest reference to glycogen storage in the human placenta dating to the early 
20th Century (Driessen, 1907), understanding its role during normal or complicated 
pregnancies has remained an elusive goal. In the human placenta, glycogen is predominantly 
found in the cytotrophoblast cells (Wislocki and Bennett, 1943), with the highest levels in the 
distal cytotrophoblast closest to the decidua (Georgiades et al., 2002). In uncomplicated 
pregnancies, placental glycogen content peaks towards the end of the first trimester before 
declining towards term (Villee, 1953, Robb and Hytten, 1976, Boyd, 1959). Aberrant glycogen 
storage was reported in gestational diabetes (Heijkenskjold and Gemzell, 1957, Diamant et 
al., 1982, Gabbe et al., 1972, Desoye et al., 1992, Gheorman et al., 2013) and preeclampsia 
(PE) (Arkwright et al., 1993, Tsoi et al., 2003), suggesting a possible role in the pathogenesis 
of these two common pregnancy complications. The relevance of aberrant glycogen storage 
in the context of human pregnancy complications has been reviewed elsewhere (Akison et 
al., 2017). However, one hypothesis suggests that in diabetic pregnancies the placenta stores 
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excess glucose as glycogen to protect the fetus from maternal hyperglycaemia, thus limiting 
fetal overgrowth (Desoye et al., 2002).
Considerable constraints limit our ability to explore placental glycogen function in 
humans, such as the lack of available tissue at the appropriate developmental stage. 
Accordingly, it is necessary to turn to the mouse model, which benefits from large litter sizes, 
a short gestation period that allows for the investigation of early pregnancy, and a similar 
genome to humans that is easily manipulated. There are 47 known mouse models with 
targeted mutations that display phenotypes associated with the trophoblast cell subtype that 
stores glycogen. A common feature among these placental mutants is that fetal growth is co-
ordinately affected. Therefore, use of these mutant mouse lines will help to elucidate the 
normal physiological role of placental glycogen and may provide further insight to the 
relevance of placental glycogen in the human placental during normal and complicated 
pregnancies.
Placental development in the mouse
The mouse is a particularly useful model for the human placenta, since they are both 
haemochorial, are architecturally similar and express many of the same genes that regulate 
placental development and function (Rossant and Cross, 2001). In particular, imprinted genes, 
which are characterised by expression derived wholly, or predominantly, from one or other 
parental allele, exert significant influence on placental development in both humans (Frost 
and Moore, 2010) and mice (Tunster et al., 2013). Furthermore, the mouse placenta also 
accumulates glycogen stores in a specialised trophoblast cell subtype called the glycogen 
trophoblast (GlyT), some of which interact intimately with the maternal decidua (Coan et al., 
2006, Bouillot et al., 2005, Rampon et al., 2005). For this reason, GlyT cells share similarities 
with human cytotrophoblast cells, and establish the mouse as an ideal model in which to 
elucidate the function(s) of placental glycogen stores.
In the mouse, GlyT appear in cell clusters in the junctional zone (Jz) of the mature 
placenta, before a proportion of these cells invade the maternal decidua to congregate 
around maternal spiral arteries (Adamson et al., 2002). When considering how defects in 
placental glycogen storage and metabolism emerge, it is important to consider when GlyT 
first arise during placental development, and whether defective GlyT differentiation is the 
primary cause of altered placental glycogen content. Development of the mouse placenta 
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under normal circumstances has been extensively reviewed elsewhere (Watson and Cross, 
2005, Rossant and Cross, 2001). Briefly, by implantation at embryonic day (E) 4.5, the mouse 
blastocyst comprises a layer of trophectoderm that surrounds the inner cell mass (ICM). The 
trophectoderm cells immediately adjacent to the ICM proliferate to give rise to two main 
trophoblast progenitor populations: the ectoplacental cone (EPC), which will differentiate to 
yield cells of the centrally located junctional zone (Jz) that is predominantly endocrine in 
function; and the extraembryonic ectoderm (ExE), which will eventually give rise to the 
labyrinth zone (Lz) where, when vascularised by fetal capillaries, nutrient, gas and waste 
exchange between maternal and fetal blood circulations occurs (Fig 1).
To date, nine trophoblast cell subtypes are known to differentiate from these 
progenitor populations. These include the spongiotrophoblast (SpT) and GlyT cells, which 
share a common EPC progenitor, and together with parietal trophoblast giant cells (P-TGCs), 
comprise the mature Jz. SpT cells function predominantly in the production of hormones, 
including members of the Prl (prolactin/placental lactogen-related) and Psg (pregnancy 
specific glycoprotein) gene families. The GlyT lineage is named for the abundant stores of 
glycogen that they accumulate and metabolise during gestation. In total, five TGC sub-types 
have been identified. Based upon lineage tracing, gene expression profiles and spatial 
localisation within the placenta (Fig 1), it is hypothesised that most of the TGCs also derive 
from the EPC (Simmons et al., 2007, Gasperowicz et al., 2013). TGCs associate with the 
maternal blood sinuses throughout the placenta and secrete hormones into the maternal 
circulation to modulate maternal physiology and placenta function. Sinusoidal-TGCs (S-TGCs) 
are located within the Lz, and together with a bilayer of syncytiotrophoblast (SynT-I and SynT-
II) cells derived from the ExE, they create a trilaminar cellular arrangement that separates the 
maternal circulation from the extensively branched fetal vasculature (Adamson et al., 2002, 
Watson and Cross, 2005, Simmons et al., 2008a).
Based on lineage tracing experiments (Simmons and Cross, 2005), GlyT cells share a 
common Tpbpa+ EPC progenitor with SpT cells and arise early in development. Periodic acid-
Schiff (PAS) staining, which is a general staining method used to detect polysaccharides (e.g. 
glycogen) in addition to mucosubstances (e.g. glycoproteins and glycolipids), demonstrates 
small quantities of glycogen are stored by GlyT from ~E5.5 (Tesser et al., 2010), suggesting 
that GlyT are specified soon after implantation. An early lineage split of the GlyT and SpT 
populations is further suggested by expression of the GlyT-specific marker genes Pcdh12 and 
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Aldh1a3 in a subset of EPC cells from ~E7.5 and ~E8.5, respectively (Rampon et al., 2005, 
Bouillot et al., 2005, Outhwaite et al., 2015). GlyT number expands nearly 300-fold between 
E12.5 and E16.5 before declining ~60% by E18.5 (Coan et al., 2006). This expansion coincides 
with a marked increase in PAS staining from E12.5 (Adamson et al., 2002), which distinguishes 
GlyT from the adjacent SpT cells (Fig 2A-C). By comparison, the SpT population increases less 
than four-fold during the same period, with a modest ~20% reduction by E18.5 (Coan et al., 
2006). During this developmental timeframe, placental glycogen stores peak at ~E15.5 before 
declining by ~50% at E18.5 (Lopez et al., 1996) as the GlyT cell population diminishes. Even 
though both GlyT and SpT cells continue to express the Jz-marker gene Tpbpa in the mature 
placenta (Lescisin et al., 1988) (Fig 2D, E), other GlyT-specific markers have been described, 
including the gap-junction genes Gjb3 (Cx31) and Gjb5 (Cx31.1), which are localised to GlyT 
cells from ~E12.5 (Coan et al., 2006) and E13.5 (Zheng-Fischhofer et al., 2007), respectively, 
alongside persistent expression of Pcdh12 (Fig 2F-H).
The putative role of placental glycogen
Studies in animal models have led to the hypothesis that placental glycogen stores provide a 
source of glucose to support fetal growth during late gestation (Coan et al., 2006). This 
hypothesis is supported by two observations; glycogen acts as the primary energy store in 
animals, and placental glycogen diminishes towards the end of pregnancy coincident with a 
period of rapid fetal growth. However, little experimental evidence currently exists to directly 
support such a function. The location of GlyT cells next to maternal blood sinuses may provide 
some indication as to the ultimate destination of the glucose released from placental 
glycogen stores. For instance, from ~E12.5 some GlyT invade the decidua where they localise 
in close proximity to maternal spiral arteries, and by E16.5 account for ~30% of the total GlyT 
population (Coan et al., 2006, Redline et al., 1993, Gasperowicz et al., 2013) (Fig 1). Based on 
this association, it is possible that migratory GlyT cells metabolise glycogen into glucose for 
transport into the maternal blood entering the placenta for eventual fetal uptake. Indeed, 
large lacunae form in the decidua by E17.5 that are presumed to result from the lysis of 
multiple GlyT in the vicinity (Bouillot et al., 2005). In contrast, populations of non-migratory 
GlyT cells cluster in close proximity to channels in the Jz that drain maternal blood from the 
placenta (Gasperowicz et al., 2013) (Fig 1). Whether these GlyT cells release glucose or other 
factors, such as hormones, into maternal blood to influence maternal physiology in 
Page 6 of 48
reproduction@bioscientifica.com
Manuscript submitted for review to Reproduction
For Review Only
preparation for parturition and lactation (Napso et al., 2018) to indirectly support fetal growth 
and wellbeing is yet to be determined. Beyond location, the migratory and non-migratory 
GlyT populations are distinguishable by expression of distinct Prl genes: migratory GlyT 
express Prl7b1 whilst non-migratory GlyT express Prl6a1 (Simmons et al., 2008b). Further 
experiments are necessary to explore functional differences between these GlyT subtypes. 
Simultaneously, it is also possible that placental glycogen stores might provide energy directly 
to the placenta, since it is a highly metabolic organ that consumes a considerable proportion 
of the glucose delivered to it (Hay, 1995). Indeed, placental glycogen stores might fuel 
hormone production by the placenta (e.g. Prl and Psg gene family members), which increases 
dramatically towards term (Simmons et al., 2008b, McLellan et al., 2005).
How placental glycogen is metabolised is not well understood. Glucagon might play a 
role in stimulating the release of glycogen stores from GlyT (Coan et al., 2006). Yet, placental 
glycogen content is unaltered in mice deficient for the glucagon receptor (Ouhilal et al., 2012) 
indicating that an alternative pathway might be involved. However, only a small number of 
glucagon receptor mutants were examined at a single developmental time-point with no 
consideration of fetal sex. Fetal sex was shown to influence placental glycogen content, at 
least in the spiny mouse (O'Connell et al., 2013). Therefore, a role for glucagon in regulating 
glycogen metabolism cannot currently be excluded. Additional models are required to more 
fully understand the enzymes important for glycogen metabolism in the mouse placenta.
Common functionality of genes involved in GlyT development and function
Of the 47 mutant mouse lines that are known to exhibit GlyT phenotypes (with or without 
aberrant glycogen storage), 38 different genes are represented. As the list lengthens, 
common genetic pathways and gene classifications have emerged as important players in 
GlyT formation and function. The majority of these genes can be assigned to at least one of 
three functional groups (Table 1): imprinted and X-linked genes, cell signalling genes, and 
genes involved in transcriptional regulation.
Imprinted and X-linked genes
Imprinted genes represent an unusual class of autosomal gene that are characterised by 
complete or partial parental-allele-biased expression. This means that gene expression is 
derived wholly, or predominantly, from either the maternally inherited allele (i.e. maternally 
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expressed) or paternally inherited allele (i.e. paternally expressed) in one or more tissues. In 
excess of 100 imprinted genes have been reported in the mouse, many of which are known 
to regulate placental development and function (Tunster et al., 2013). A broad role for 
imprinted genes in regulating the GlyT lineage has been reviewed previously (Lefebvre, 2012), 
whereby four genes (Ascl2, Cdkn1c, Igf2, Phlda2) that reside within a ~1 Mb imprinted region 
on mouse distal chromosome 7 were discussed in detail. In addition to these genes, the 
paternally expressed Dlk1, Peg3 and Peg10 genes are also implicated in regulating the GlyT 
lineage and/or placental glycogen stores (Table 1), further emphasising the importance of 
imprinted genes in regulating placental glycogen stores.
A special class of imprinted genes is the X-chromosome-linked genes. To ensure 
similar gene dosage between males and females, one X chromosome in female cells is 
silenced. In extraembryonic lineages of female mouse conceptuses, the paternally inherited 
X-chromosome is preferentially silenced (Takagi and Sasaki, 1975). A role for X-lined genes in 
regulating placental glycogen storage is demonstrated by mice that inherited only a single 
paternally inherited X chromosome (XpO) and display and expansion of the GlyT population 
(He et al., 2017). In support of this hypothesis, GlyT phenotypes were reported to varying 
degrees in loss-of-function models of four X-linked genes (i.e. Plac1, Ldoc1, Wdr1 and Esx1) 
(Table 1). The functional convergence of imprinted and X-linked genes in regulating placental 
glycogen storage is consistent with the established role of imprinted genes in modulating fetal 
nutrient supply across the placenta (Tunster et al., 2013, Angiolini et al., 2006) and with the 
purported function of placental glycogen stores in providing an energy source to support fetal 
growth during late gestation. With the majority of imprinted genes exhibiting placental 
expression in the mouse, it will be of interest to explore whether other imprinted genes are 
involved in regulating placental glycogen storage.
Cell-cell signalling
Studies of mutant mouse lines that report glycogen storage defects that arise secondary to 
SpT phenotypes implicate a role for SpT-derived signals in the regulation of placental glycogen 
metabolism. For instance, genetic knockout or over-expression of the maternally expressed 
imprinted gene Phlda2 causes an expansion or reduction of the SpT population, respectively 
(Tunster et al., 2015, Tunster et al., 2010, Tunster et al., 2014). Unaltered expression of the 
GlyT marker genes Pcdh12 and Gjb3 suggested there was no overt effect on GlyT population 
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size in either model. However, placental glycogen content closely paralleled the SpT 
phenotype, with a reduced SpT population leading to diminished glycogen content and an 
expanded SpT population associated with increased glycogen storage (Tunster et al., 2015, 
Tunster et al., 2010, Tunster et al., 2014). These studies implicate cell-to-cell signalling 
between SpT and GlyT, though the specific pathways that mediate this effect are unclear. A 
clue might lie within the Crim1 knockout model. Crim1 encodes for a transmembrane protein 
that mediates signal transduction by binding growth factors (e.g. vascular endothelial growth 
factor A; VEGF-A) to the cell surface. While Crim1 mRNA expression is limited to SpT cells, the 
GlyT population expands in the absence of CRIM1 function (Pennisi et al., 2012). Therefore,  
CRIM1 might regulate a SpT-derived factor that signals to GlyT to regulate their proliferation 
(Pennisi et al., 2012).
Further evidence for a role of SpT-derived signals in modulating placental glycogen 
stores is provided by a comparison of Phlda2 null conceptuses and their wildtype littermates 
with strain-matched control litters. Loss of function of Phlda2 results in expansion of the Jz 
(Frank et al., 2002), which is attributable to a disproportionate increase in the SpT population 
(Tunster et al., 2015). While there was no overt effect on GlyT cell number, an accumulation 
of glycogen in placentas from Phlda2 null and their wild type littermates was apparent at 
E18.5. One explanation might be that the entire litter was exposed to an enhanced endocrine 
signalling environment caused by SpT expansion in Phlda2 null placentas resulting in excessive 
placental glycogen storage that potentially deprives the fetuses of nutrients (Tunster et al., 
2015). However, it is not possible to exclude a role for broader effects on maternal physiology 
in impairing fetal growth in this model.
We have identified a further fourteen genes that encode for specific components of 
cell signalling pathways that might help to establish the importance of cell-cell signalling in 
the regulation of placental glycogen content (Table 1). These genes include signalling 
molecules such as cytokines (Csf2), hormones (Pthlh, Prl7d1) and growth factors (Pgf), 
receptors (Egfr) and downstream effectors, such as kinases (Akt1, Pik3ca) and phosphatases 
(Ptp4a2). Some of these genes encode for key intermediates in a diverse range of signalling 
pathways, namely VEGF (e.g. Crim1), epidermal growth factor (EGF) (e.g. Egfr) and 
transforming growth factor (TGF) (e.g. HtrA1) pathways. 
In particular, aberrant AKT signalling is implicated in GlyT phenotypes associated with 
genetic knockouts of Ptp4a2, Tfap2c, Igf2 or Phlda2 (Sharma et al., 2016, Takao et al., 2012, 
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Sferruzzi-Perri et al., 2017, Dong et al., 2012, Saxena et al., 2002, Frank et al., 1999). This, 
combined with the fact that loss of function of Akt1 itself impairs placental glycogen storage 
(Yang et al., 2003), indicates that the AKT pathway is key to this process. AKT signalling is 
known to regulate specific cellular processes including growth, proliferation, metabolism and 
survival (Manning and Toker, 2017, Yu and Cui, 2016, Hermida et al., 2017). Specific to its role 
in glycogen storage, AKT also regulates glycogenesis through the inhibition of glycogen 
synthase kinase 3 (GSK3), a negative regulator of glycogen synthase (Cross et al., 1995, Diehl 
et al., 1998). Other models that show changes in the expression of Igf2 or Phlda2 (e.g. Pcdh12 
knockout (Rampon et al., 2008)) might also implicate AKT signalling defects in their GlyT 
phenotypes. While aberrant AKT signalling was reported in the placentas of human FGR 
infants (Yung et al., 2008), placental glycogen storage has not yet been investigated in the 
context of human FGR to date.
Ablation of Akt1, which encodes for protein kinase B (PKB), causes fetal and 
placental growth restriction (Yang et al., 2003). A near complete loss of glycogen-containing 
trophoblast cells was reported (Yang et al., 2003), though this result was based solely on 
examination of PAS-stained placenta sections. The absence of PAS staining is more likely to 
indicate a failure to accumulate glycogen, rather than ablation of the GlyT lineage. Therefore, 
this model should be revisited for a more detailed analysis of the GlyT phenotype, including 
determination of spatiotemporal expression of markers such as Pcdh12 (Bouillot et al., 2005), 
Gjb3 (Coan et al., 2006), Aldh1a3 (Outhwaite et al., 2015) and biochemical analysis of 
glycogen content (Lo et al., 1970). Regardless, the result is consistent with the role of AKT in 
regulating GSK3, and indirectly, glycogen synthase (Yang et al., 2003).
Upstream regulators of AKT signalling include PRL2 and IGF2, both of which have been 
implicated in placental development. The Ptp4a2 gene encodes for the protein phosphatase 
PRL2 and when knocked out the placentas were small in size due to a substantially reduced 
Jz defined by a near complete loss of SpT with only a few non-migratory GlyT remaining (Dong 
et al., 2012).  Whilst PAS staining was reduced, placental glycogen content was not directly 
quantified (Dong et al., 2012). Ptp4a2-/- placentas also exhibited reduced AKT phosphorylation 
(Dong et al., 2012) indicating that PRL2 is important for this process. The associated Ptp4a2-/- 
fetuses were growth restricted at E16.5. In fetal tissues, AKT and MAPK (mitogen activated 
protein kinase) pathways are activated via IGF2 signalling mediated primarily through binding 
IGF1R (insulin like growth factor 1 receptor) (Sferruzzi-Perri et al., 2017, Forbes and 
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Westwood, 2008). However, the absence of a placental phenotype in Igf1r null mice suggests 
that IGF2 acts through an alternative, unknown receptor in the placenta (Baker et al., 1993, 
Efstratiadis, 1998). Whether IGF2 activates AKT signalling in the placenta is unclear, and a 
detailed assessment of AKT signalling in the placenta of Igf2 mutants is required. Additionally, 
further work is warranted to explore the broad role of AKT signalling in regulating placental 
glycogen stores by utilising mouse models with known GlyT phenotypes.
Transcriptional regulators
The GlyT population is highly dynamic from, with the number of GlyT cells increasing by nearly 
300-fold between E12.5 and E16.5, and switching from an apparently glycogenic state to a 
glycogenolytic state (Lopez et al., 1996). These changes implicate major shifts in 
transcriptional regulation to modulate placental glycogen metabolism. A broad role for 
transcriptional regulators in modulating placental glycogen storage and/or the GlyT lineage 
has not been previously recognised. We identified eight genes encoding specific 
transcriptional regulators that are implicated in the development and/or function of the GlyT 
lineage (Table 1). One example is the endothelial-specific microRNA miR-126a (miR-126), 
which when ablated leads to global hypermethylation associated with dysregulated 
expression of placenta-specific genes (e.g. Prl6a1, Pcdh12 and Tpbpa), and imprinted genes 
(e.g. Igf2, Phlda2 and Cdkn1c) (Sharma et al., 2019). Genetic ablation of miR-126a results in 
Jz hyperplasia, attributable to a specific expansion of the GlyT population, without a change 
in SpT abundance. Consequently miR-126a-/- placentas accumulated ~50% more glycogen 
than controls and were associated with fetal growth restriction at E15.5 (Sharma et al., 2019). 
The specific targets of miR-126a are yet to be determined. Further work is required to fully 
elucidate the transcriptional networks involved in regulating the GlyT lineage and glycogen 
storage.
Using genetic mouse models to understand the function of placental glycogen
The association of altered placental glycogen storage with human pregnancy complications 
supports an important role for glycogen in achieving a successful pregnancy outcome 
(reviewed in Akison et al., 2017). The majority of mouse models with GlyT phenotypes show 
evidence of fetal growth restriction (FGR), which is consistent with the putative role of 
placental glycogen in supporting fetal growth (Tables 2 and 3). In contrast, the remaining 
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models showed GlyT phenotypes that were either associated with normal, enhanced or 
undetermined effects on fetal growth (Table 4), or embryonic lethality around mid-gestation 
(Table 5) that precluded a meaningful assessment of fetal growth.
In our evaluation of the literature, we observed that the extent to which GlyT 
phenotypes are characterised varies considerably between studies. Indeed, only a minority 
of these models was assessed using a direct biochemical determination of placental glycogen 
content. Instead, reduced glycogen storage or mobilisation was inferred from one or more of 
the following methods: reduced (or absent) PAS staining; reduced GlyT abundance as 
determined by histology and/or reduced genetic marker expression for GlyT cells; 
mislocalisation of GlyT within the Lz or a failure of GlyT cells to migrate to the decidua. As a 
result, there is a need for established criteria in describing GlyT phenotypes and glycogen 
storage and metabolic defects. We identified four key parameters for characterising GlyT 
phenotypes: 1. GlyT lineage specification and differentiation by assessing lineage marker 
expression, 2. GlyT cell number, 3. GlyT localisation and degree of migration into the decidua, 
and 4. Quantification of total placental glycogen content using a biochemical assay (Lo et al., 
1970). A collective evaluation of these genetic mutants using these criteria will help to 
separate GlyT developmental defects from metabolic/storage defects and improve our 
understanding of how placental glycogen stores support growth.
Reduced placental glycogen content is frequently associated with fetal growth restriction
Several mouse models that demonstrate a glycogen storage deficit are also associated with 
FGR (Table 2). It is well known that IGF2 is an important regulator of fetal and placental 
growth (DeChiara et al., 1990, Constância et al., 2005). Igf2 mRNA is highly expressed in the 
GlyT lineage (Georgiades et al., 2002, Redline et al., 1993, Coan et al., 2006) and constitutive 
deletion of Igf2 results in reduced GlyT abundance and placental glycogen content (Lopez et 
al., 1996). Deletion of the placenta-specific Igf2 transcript (Igf2P0) results in a similar 
reduction of GlyT cell number (Sferruzzi-Perri et al., 2011), even though the Igf2P0 transcript 
accounts for only 10% of total placental Igf2 (Moore et al., 1997). Whilst constitutive deletion 
of Igf2 results in a 50% reduction in fetal weight (DeChiara et al., 1990), Igf2P0 mutants are 
25% lighter than controls (Constância et al., 2005), at least partially attributing FGR to a 
placental defect. However, the contribution of placental glycogen is unclear as glycogen 
content was not directly assessed in the Igf2P0 mutants.
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Human placentas exhibiting elevated expression of PHLDA2 are frequently linked with 
FGR (reviewed in Jensen et al., 2014), although placental glycogen stores have not been 
investigated in these placentas. Analysis of a mouse model with over-expression of Phlda2 
demonstrates that placental glycogen content is reduced by 50% of controls. However, the 
effect on glycogen storage is likely secondary to a reduction in the Prl8a8+ SpT population 
since there was no overt effect on expression of the GlyT markers Pcdh12 or Gjb3 (Tunster et 
al., 2010, Tunster et al., 2014, Tunster et al., 2015). The effect on fetal growth in the Phlda2 
over-expression model is complex and dependent upon the genetic background of the mouse, 
even though similar placental defects are apparent between strains. For instance, fetal 
growth was asymmetrically restricted when on the 129S2/SvHsd background (Salas et al., 
2004, Tunster et al., 2010), but was unaffected on the C57BL/6 background (Tunster et al., 
2014). Since genetically wildtype placentas on the C57BL/6 background naturally accumulate 
more than twice the glycogen content of 129S2/SvHsd placentas (Tunster et al., 2012), fetal 
growth might be protected on the C57BL/6 background. 
Even though GlyT are important for fetal growth, these cells are not essential to fetal 
survival. GlyT cells were absent in mutant mouse lines whereby the expression of Ascl2 was 
at ~50% of endogenous levels (Ascl2LacZ/Del7AI or Del7AI/+ mutants). Placentas either 
demonstrated a lack of PAS stain and/or Pcdh12 expression at E15.5. The associated fetuses 
survived to term, albeit exhibiting growth restriction of 15-20% (Lefebvre et al., 2009, Oh-
McGinnis et al., 2011, Bogutz et al., 2018). In contrast, Ascl2 null placentas lack the EPC 
progenitor cells that give rise to the SpT and GlyT resulting in embryonic lethality at mid-
gestation (Guillemot et al., 1994). Therefore, Ascl2 is likely required for the formation of GlyT 
cells and might also be associated with glycogen storage or metabolism.
Beyond GlyT differentiation, several mouse strains demonstrate abnormal localisation 
of GlyT (Table 2). Normally, GlyT are present in the Jz with a subpopulation of GlyT migrating 
into the decidua (Coan et al., 2006). Ldoc1, HtrA1 and Tfap2c single knockout mutations lead 
to placentas with GlyT that have mislocalised to the Lz (Hasan et al., 2015, Naruse et al., 2014, 
Kaiser et al., 2015). The Jz naturally interdigitates with the Lz (Soares and Hunt, 2014), with 
the extent to which depends upon gestational stage and genetic background (Tunster et al., 
2012). Therefore, it is important to be cautious when histologically characterising clusters of 
GlyT located in the Lz. Serial sections of placenta can be assessed to differentiate a GlyT 
cluster from a Jz finger protruding in to the Lz. Alternatively, failure of GlyT to migrate into 
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the decidua, as in Ptp4a2-/- or Phlda2 over-expression mice (Dong et al., 2012, Tunster et al., 
2010), might affect maternal-fetal interactions. Whether defective GlyT migration in these 
models results from altered cell-signalling pathways associated with adhesion and 
cytoskeleton, or an inappropriate response to chemotactic signals remains to be determined. 
However, appropriate localisation of GlyT appears to be important for normal fetal growth.
Increased placental glycogen storage is also associated with impaired fetal growth
Unexpectedly, FGR can also occur in the context of increased placental glycogen storage. For 
example, when the number of GlyT cells exceeded 35% of the Jz as in interspecific mouse 
hybrids, fetal growth was inversely correlated with GlyT abundance (Kurz et al., 1999). 
Additionally, several genetic mouse lines exist that demonstrate increased placental glycogen 
storage associated with FGR (Table 3). One potential explanation for these counterintuitive 
findings is that the mutant placentas are able to store glycogen but cannot effectively mobilise 
and release the glycogen. Further work is necessary to elucidate the mechanism, with a 
specific focus on whether glycogenesis is increased, leading to enhanced glycogen storage, 
whether glycogenolysis is impaired, leading to failed glucose release, or whether transport 
mechanisms are defective. Alternatively, FGR in models associated with increased placental 
glycogen storage might be caused by a mechanism independent of the GlyT or placental 
glycogen. Of note, some models (e.g. Ascl2-Tg, Pcdh12-/- and Plac1-/-) with increased glycogen 
storage also display mislocalisation of GlyT clusters withi  the Lz (Tunster et al., 2016, Rampon 
et al., 2008, Jackman et al., 2012). This result is consistent with a role for the normal 
microenvironment of the Jz in modulating the mobilisation of glycogen stores by the GlyT.
Enhanced fetal growth might be independent of a GlyT phenotype
It is possible for enhanced fetal growth to associate with aberrant placental glycogen storage, 
as occurs in Cdkn1c-/+ and H19-/- mice (Tunster et al., 2011, Esquiliano et al., 2009) (Table 4). 
However, it is unlikely that these placental phenotypes directly cause fetal overgrowth since 
these genes exert an intrinsic effect on fetal growth. For instance, conditional over-expression 
of Cdkn1c in a subset of fetal, but not placental, tissues restricts fetal growth (Andrews et al., 
2007, John et al., 2001). In contrast, whilst Cdkn1c knockout mice exhibit fetal overgrowth 
and placentomegaly at E15.5 and E18.5, fetal weights are normalised at birth (Tunster et al., 
2011). This failure to sustain fetal over-growth may be attributable to the manifestation of 
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severe defects in Cdkn1c-/+ placentas including substantially diminished glycogen stores 
(Tunster et al., 2011), although GlyT abundance is unaffected (Takahashi et al., 2000). 
Similarly, ablation of H19 drives over-expression of the growth-promoting gene Igf2, resulting 
in neonates that are 30% heavier than their littermates (Leighton et al., 1995), and placentas 
with increased GlyT number and placental glycogen content (Esquiliano et al., 2009). 
However, since the H19-driven fetal over-growth phenotype persists to adulthood, the cause 
is likely independent of increased placental glycogen stores.
GlyT phenotypes associated with early embryonic lethality
Several genetic mouse models display a GlyT phenotype and result in embryonic lethality at 
or around mid-gestation (Table 5). This outcome occurs before GlyT cells mature and begin 
accumulating glycogen stores in earnest. Early fetal demise prevents a meaningful 
assessment of the effect of placental glycogen stores on fetal growth in this context. It is clear 
that embryonic lethality is attributable to a placental defect in the case of Ascl2 and Peg10 
knockouts, since lethality was rescued using a tetraploid aggregation approach (Guillemot et 
al., 1995, Guillemot et al., 1994, Ono et al., 2006). This method generates a chimeric 
conceptus in which a mutant fetus is supported by a placenta containing wild-type tetraploid 
cells (Nagy et al., 1990, Tarkowski et al., 1977). In this context, rescue of embryonic lethality 
indicates a placental cause. Embryonic lethality in the remaining models coincides with the 
appearance of congenital malformations (Table 5). A conditional knockout approach is 
required to elucidate the role of these genes in later stage placentas, including in GlyT 
development and function. A recent study demonstrated that defects in placental 
development and/or function might contribute to the formation of congenital malformations 
in the fetus, particularly those affecting heart, brain and vascular development (Perez-Garcia 
et al., 2018). The extent to which GlyT and placental glycogen stores play a role in this 
phenomenon is yet-to-be determined.
Limitations
Whilst the studies presented here broadly support a role for placental glycogen in regulating 
fetal growth, a major limitation to understanding the true cause-effect relationship is that the 
Lz structure is also disrupted in many of these models (Tables 2-5). The Lz facilitates the 
exchange of nutrients, gases and waste products between maternal and fetal circulations 
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(Watson and Cross, 2005). Reduced branching morphogenesis in the Lz decreases the surface 
area for nutrient transport, compromising placental function (Cross et al., 2006). 
Consequently, it is difficult to directly attribute the adverse fetal growth outcomes specifically 
to aberrant placental glycogen storage for most genes. One model whereby fetal growth and 
placental glycogen content might show a direct link is a hypomorphic Egfr mutation. These 
mutant mice have placentas with a GlyT-specific phenotype characterised by reduced PAS 
staining and diminished GlyT marker expression but no other placental defect. Associated 
fetuses were growth restricted in a background-specific manner, with Egfr hypomorphs that 
restricted on the 129Sv and BTBR/J backgrounds but not the C57BL/6J background (Dackor et 
al., 2009). Crucially, whilst PAS staining of Egfr hypomorphic placentas was reduced on the 
129Sv and BTBR/J backgrounds, abundant PAS staining was evident on the C57BL/6 genetic 
background (Dackor et al., 2009). This emphasises a potential relationship between glycogen 
storage and fetal growth.
The ability to ascertain the mechanism driving aberrant glycogen storage from existing 
studies is difficult given that GlyT abundance and total placental glycogen content are not 
always assessed together. Therefore, it is unclear whether an early defect in GlyT progenitor 
maintenance or differentiation leading to a reduction in mature GlyT cells is the main cause 
of glycogen storage defects. This appears to be the case for at least eleven mutant mouse 
lines where both parameters have been assessed (Table 1). The majority of studies have 
assessed only a single parameter: GlyT abundance or placental glycogen content. This will 
affect the conclusions drawn by each study and not necessarily reflect whether the 
mechanism is developmental or metabolic in origin. The only known model whereby placental 
glycogen stores are independent of GlyT differentiation and abundance is the Cdkn1c null line 
(Tunster et al., 2011, Takahashi et al., 2000). From this model, we might better understand 
how glycogen metabolism occurs in the placenta and how fetal growth responds. 
Future directions
Considerable work is required to fully elucidate the normal physiological role of placental 
glycogen stores in humans given that we are only beginning to understand its role during 
pregnancy. To improve our understanding, a systematic analysis of the GlyT population is 
required in known mouse models with placenta phenotypes and as part of the routine 
assessment of new mouse placenta phenotypes. We have proposed four key parameters to 
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assess the GlyT lineage to better understand their development and function: 1) 
Quantification of GlyT cell number as determined by nuclear counts on histological sections; 
2) Assessment of GlyT specific marker gene expression (e.g. Pcdh12, Aldh1a3, Gjb3) either by 
in situ hybridisation on histological sections (Fig 2) or by qPCR analysis at multiple stages of 
development. This should occur in concert with assessment of other trophoblast lineage 
marker expression; 3) Analysis of the localisation of GlyT cells by undergoing in situ 
hybridisation for the migratory (Prl7b1) and non-migratory (Prl6a1) markers. This will indicate 
the migratory capacity of these cells and whether placental structure is affected; and 4) 
Exploring placental glycogen content by performing PAS-staining of histological sections (Fig 
2) alongside quantification of total placental glycogen content using a biochemical assay (Lo 
et al., 1970). Altogether, these criteria will help to direct subsequent phenotype evaluation, 
and ultimately identify further molecules and pathways important for GlyT formation and 
function, and for the regulation of placental glycogen stores. 
Given the highly dynamic nature of the GlyT cells over the course of pregnancy, it is 
important to assess placental glycogen-related phenotypes (and arguably other placental 
phenotypes) at multiple gestational stages. Characterisation of a single developmental stage 
might misrepresent the full extent of the phenotype. One model that exemplifies this issue is 
the Pthlh knockout mouse (Duval et al., 2017), whereby placental glycogen content was 
reduced at E12.5 and E14.5. By E16.5, glycogen had normalised to control levels. However, 
glycogen content was elevated at E18.5 relative to controls, failing to exhibit the anticipated 
decline towards term that is normally attributed to the mobilisation of glycogen stores in late 
gestation. Coinciding with the glycogen phenotype, fetal growth was restricted from E16.5 
(Duval et al., 2017). Although Pthlh-null mice exhibit severe skeletal abnormalities and die 
soon after birth (Karaplis et al., 1994, Bond et al., 2008), the late-onset FGR observed in this 
model implicates a causal role for placental dysfunction. However, it is unclear whether FGR 
can be attributed to impaired glycogen storage during mid-gestation or the apparent failure 
to mobilise placental glycogen stores at term. Assessing phenotypes at multiple stages of 
development will potentially allow for better separation of developmental defects from 
functional defects.
The regulation of glycogenesis and glycogenolysis pathway activity by GlyT will provide 
further insight into placental glycogen metabolism. Central to glucose release from a cell is 
the enzyme glucose 6-phosphatase, which is responsible for generating free glucose by 
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hydrolysing the polar phosphate group from glucose 6-phosphate and allowing its transport 
out of the cell (van Schaftingen and Gerin, 2002). The absence of glucose 6-phosphatase 
activity in GlyT cells would prevent the release of glucose for consumption by the fetus, 
mother or trophoblast cells. While expression of glucose 6-phosphatase has not been 
investigated in the mouse placenta to date, its activity in the human placenta is attributed to 
the G6PC3 isoform (Guionie et al., 2003). This isoform is distinct from the liver-specific G6PC1 
isoform, and is expressed in the placenta from at least week 28 of human pregnancy 
(Matsubara et al., 1999), and may be associated with the production of glucose in the 
placenta at term (Prendergast et al., 1999). However, the ultimate destination of glucose 
derived from placental glycogen stores remains unclear. It is possible that it is directed for 
fetal use and/or placental consumption. Signals from the fetus that release placental glycogen 
stores have not been identified.
It is also possible that placental glycogen stores support maternal physiology. The 
localisation of non-migratory GlyT around channels that drain maternal blood from the 
placenta suggests that some of the glucose released from placental glycogen stores may first 
be available for uptake by the mother. GlyT express several Prl genes and the localisation of 
non-migratory GlyT suggest the encoded hormones may be released into maternal blood. 
Whilst placental hormones are known to adapt maternal physiology to pregnancy, there is 
currently no evidence that the glucose metabolised from placental glycogen stores acts to the 
benefit of maternal physiology. Future studies should assess the effects of aberrant placental 
glycogen storage on maternal physiology. Indeed, genetic perturbations of several genes that 
regulate the GlyT lineage also have effects on maternal behaviour, including Peg3 (Li et al., 
1999, McNamara et al., 2018) and Phlda2 (Creeth et al., 2018). Little is known about changes 
to maternal physiology in these models. Dlk1+/- mice are the only model in which maternal 
physiology was characterised in association with a placental GlyT phenotype (Cleaton et al., 
2016, Appelbe et al., 2013). However, the effects on maternal physiology are more likely 
attributable to the loss of circulating DLK1 (also known as fetal antigen-1; FA1), rather than a 
consequence of altered placental glycogen metabolism. 
Conversely, there is evidence that maternal physiology can regulate placental 
glycogen stores. A loss of function allele of Pik3ca, which encodes for the catalytic subunit of 
phosphatidylinositol 3-kinase (PI3K), showed a maternal zygotic effect resulting in diminished 
glycogen stores (Sferruzzi-Perri et al., 2016), although the underlying mechanism is not well 
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understood. While manipulation of maternal diet modulates fetal growth in mouse models 
(Jones et al., 2009, Zhang et al., 2005, Zhang et al., 2009), only a few studies have investigated 
the effect of maternal diet upon placental glycogen storage. Both calorie and protein 
restriction in dams impair placental glycogen storage (Gonzalez et al., 2016, Coan et al., 2010, 
Sferruzzi-Perri et al., 2011), presumably as a consequence of diminished nutrient availability. 
A high sugar, high fat (HSHF) maternal diet results in FGR at E15.5, a phenotype that is 
normalised by E18.5 (Sferruzzi-Perri et al., 2013), potentially due to increased utilisation of 
glycogen to support accelerated fetal growth during late gestation. Further work is necessary 
to explore the relationship between maternal diet, placental glycogen metabolism and fetal 
growth.
Attempts to infer the function of placental glycogen in models where the GlyT lineage 
is ablated or diminished might be confounded by additional functions of GlyT cells, which 
perform at least two additional functions to glycogen storage. Firstly, GlyT cells contribute to 
placental endocrine function as evidenced by their expression of a subset of the Prl gene 
cluster (Simmons et al., 2008b). Secondly, GlyT expression of ALDH1A3, an enzyme that 
oxidises retinal to retinoic acid, implies that GlyT might be a source of retinoic acid, which is 
an important regulator of trophoblast differentiation (Outhwaite et al., 2015). Therefore, 
alterations in the GlyT population might have profound effects on placental structure and 
function independent of glycogen storage.
Overall, better characterisation of GlyT phenotypes in mice will allow us to evaluate 
the glycogenesis and glycogenolysis pathways involved in storing and metabolising glycogen 
in normal pregnancies and pathological contexts. More sophisticated approaches to 
constitutive gene knockout models will be necessary to elucidate the specific physiological 
role(s) of placental glycogen. These analyses should include single-cell sequencing approaches 
to better understand genetic and metabolic pathways within GlyT cells together with a more 
holistic approach that relates placental structure and glycogen metabolism to fetal growth 
and development, and to maternal physiology. Only then will the normal function and 
relevance of aberrant placental glycogen stores to human pregnancy complications, such as 
PE and GDM, be clarified.
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Figure Legends
Figure 1: Structure and trophoblast lineages of the mature mouse placenta: The mature 
mouse placenta comprises three structurally and functionally distinct layers: the maternal 
decidua (Dec), junctional zone (Jz) and labyrinth zone (Lz). The junctional zone predominantly 
comprises the spongiotrophoblast (SpT) and non-migratory glycogen trophoblast (GlyT) cells. 
A proportion of GlyT migrate to the maternal decidua where they associate with maternal 
spiral arteries bringing maternal blood to the placenta. Five trophoblast giant cell sub-types 
have been described based on localisation on gene expression patterns: the parietal TGCs (P-
TGCs) form a discontinuous cell layer at the boundary between the Jz and maternal decidua; 
spiral artery-associated TGCs (SpA-TGCs) line maternal spiral arteries through the decidua; 
canal-TGCs (C-TGCs) line maternal blood canals through the Jz and Lz; sinusoidal-TGCs (S-
TGCs) replace the endothelial layer of maternal blood sinuses within the Lz; channel-TGCs 
(Ch-TGCs) surround the channels that traverse the Jz draining maternal blood from the 
placenta. Together with the S-TGCs, two layers of syncytiotrophoblast form the trilaminar 
structure of the murine labyrinth.
Figure 2: Histological methods for assessing glycogen trophoblast cells in the mouse 
placenta at E14.5. 
Histological sections of wild type (C57BL/6J) mouse placentas at E14.5 stained using (A-C) 
Periodic acid-Schiff (PAS) stain (dark pink) that labels glycogen, glycoproteins and glycolipids, 
(D-E) Tpbpa RNA via an in situ hybridisation probe (dark purple) that stains cells derived from 
the ectoplacental cone (e.g. spongiotrophoblast (SpT) and glycogen trophoblast (GlyT)), and 
(F-H) Pcdh12 RNA via an in situ hybridisation probe (dark purple) that stains GlyT. Nuclei are 
stained using (A-C) haematoxylin (blue) or (D-H) nuclear fast red (pink). Dec, maternal 
decidua; Jz, junctional zone; Lz, labyrinth zone; YS, yolk sac; UC, umbilicus (black arrow); SpA, 
spiral artery; m, maternal blood sinusoid; mGlyT, migratory GlyT (blue arrows). Dotted lines 
separate major placenta layers or trophoblast cell populations. Boxes represent regions 
shown in higher magnification to the right. Scale bars: A, D, F = 1 mm; B, E = 250 m; C = 50 
m; G, H = 100 m
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Table 1: Classification and expression of genes implicated in regulating GlyT differentiation and/or function
Symbol Gene name Function Spatial expression GlyT differentiation† Glycogen storage†† References
Imprinted and X-linked genes
Ascl2 Achaete-scute complex 
homolog 2
Maternally expressed basic helix-loop helix 
transcription factor
Highly expressed in both EPC and 
ExE during early development. 
Expression declines towards 
term
✓ ✓ (Guillemot et al., 




Maternally expressed cyclin dependent 
kinase inhibitor 
Widely expressed with high 
expression in GlyT
✕ ✓ (Georgiades et al., 
2002, Coan et al., 
2006, Matsuoka et 
al., 1995)
Dlk1 Delta-like homolog 1 Paternally expressed transmembrane 
glycoprotein. Encodes the precursor to fetal 
antigen 1 (FA1) that functions as a Notch 
antagonist.
Expressed in endothelial cells 
lining the fetal vasculature of the 
Lz. Not expressed in any 
trophoblast lineage.
✓ n/a (Yevtodiyenko and 
Schmidt, 2006, 
Baladron et al., 2005, 
Laborda, 2000)
Igf2 Insulin-like growth 
factor 2
Paternally expressed insulin-like growth 
factor 2
Highly expressed in Jz and Lz 
between E9.5 and E12.5. 
Expression subsequently declines 
dramatically in the Lz and SpT 
but remains highly expressed in 
GlyT.
✓ ✓ (Redline et al., 1993, 
Carter et al., 2006)
Peg3 Paternally expressed 
gene 3
Paternally expressed zinc finger 
transcriptional repressor
Widely expressed in the 
developing placenta
✓ ✓ (Relaix et al., 1996)
Peg10 Paternally expressed 
gene 10
Paternally expressed retrotransposon 
derived gene
Widely expressed in all 
trophoblast lineages
✓ n/a (Ono et al., 2006)
Phlda2 Pleckstrin homology-
like domain family A 
member 2
Maternally expressed pleckstrin-homology 
domain protein that inhibits the AKT 
pathway by competing for PIP targets
Highly expressed in the EPC and 
ExE. Restricted to the chorionic 
plate and syncytiotrophoblast 
layers of the Lz by E10.5. 
Expression declines dramatically 
from E12.5. Very few PHLDA2-
positive cells remain at E14.5
n/a ✓ (Frank et al., 1999, 
Frank et al., 2002, 




X-linked paired-like homeobox domain 
protein
Expressed in the EPC and chorion 
before becoming restricted to 
the Lz by mid-gestation
✓ n/a (Li et al., 1997, Li and 
Behringer, 1998)
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Plac1 Placental specific 
protein 1
X-linked putative signal peptide Placenta specific expression from 
early to mid-gestation. EPC and 
TGCs at E7.5; P-TGCs, Jz and Lz, 
by E11.5; restricted to P-TGCs by 
E14.5
n/a ✓ (Cocchia et al., 2000)
Ldoc1 Regulator of NFKB 
signalling
X-linked gene derived from long terminal 
repeat retrotransposon
Highly expressed in TGCs, EPC 
and ExE at E8.5. 
Restricted to non-migratory GlyT 
by E15.5 and absent by E18.5.
✕ n/a (Naruse et al., 2014)
Wdr13 WD repeat domain 13 X-linked member of WD-repeat protein 
family
Expressed predominantly in the 
Lz. Lower expression in the SpT 
and decidua. Not expressed in 
GlyT
n/a ✓ (Singh et al., 2015)
Cell-cell signalling
Akt1 Thymoma viral proto-
oncogene 1
Encodes protein kinase B (PKB), a 
downstream effector of the 
phosphatidylinositol 3-kinase (PI3K) 
signalling pathway
Widely expressed in all 
trophoblast lineages and fetal 
endothelium
n/a ✓ (Yang et al., 2003)
Crim1 Cysteine rich 
transmembrane BMP 
regulator 1
Transmembrane protein that binds growth 
factors such as VEGF-A to the cell surface 
Primarily expressed in SpT. Low 
expression in P-, C- and 
syncytiotrophoblast
n/a ✕ (Pennisi et al., 2007, 
Pennisi et al., 2012, 
Wilkinson et al., 
2007)
Csf2 Colony stimulating 
factor 2 (granulocyte-
macrophage)
Encodes the cytokine Granulocyte-
macrophage colony-stimulating factor 2
Expressed in the decidua and Jz ✓ n/a (Kanzaki et al., 1991, 
Robertson et al., 
1999)
Egfr Epidermal growth 
factor receptor
Encodes epidermal growth factor receptor 
(EGFR)
Expressed in Jz and Lz at E18.5 ✓ ✓ (Dackor et al., 2007)
HtrA1 HtrA serine peptidase 1 Serine protease that functions as an 
antagonist of TGF- signalling 
Expressed in P-TGCs at E7.5. 
Expression is barely detectable 
by E13.5.
✕ ✕ (Nie et al., 2005, 
Hasan et al., 2015, 
Oka et al., 2004)
Hectd1 HECT domain E3 
ubiquitin protein ligase 
1
Ubiquitin ligase that functions as a negative 
regulator of Wnt signalling 
Widely expressed in all regions of 
the placenta between E7.5 and 
E13.5.
✓ ✓ (Sarkar et al., 2014, 
Tran et al., 2013)
Igfbp1 Insulin-like growth 
factor binding protein 
1
Carrier protein for insulin-like growth factors Strongly expressed in the yolk 
sac endoderm but not expressed 
in trophoblast lineages
✓ n/a (Carter et al., 2006, 
Hwa et al., 1999)
Pcdh12 Protocadherin 12 Member of the protocadherin subgroup of 
the cadherin family of transmembrane 
Expressed exclusively in GlyT 
lineage throughout gestation
n/a ✓ (Rampon et al., 2005)
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calcium-dependent cell-adhesion proteins
Pgf Placental growth 
factor
Encodes the pro-angiogenic Placental 
Growth Factor (PlGF)
Widely expressed in the placenta 
at E10.5
✓ ✓ (Achen et al., 1997, 
Tayade et al., 2007)
Pik3ca Phosphatidylinositol-
4,5-bisphosphate 3-
kinase catalytic subunit 
alpha
Encodes the ubiquitously expressed PI3-
kinase catalytic subunit p110 
Ubiquitously expressed n/a ✓ (Foukas et al., 2006)
Prl7d1 Prolactin family 7, 
subfamily d, member 1
Member of the prolactin/placental lactogen 
(Prl/Pl) gene family
Widely expressed in all 
trophoblast sub-types; highest 
expression in GlyT
✓ ✓ (Simmons et al., 
2008)
Ptp4a2 Protein tyrosine 
phosphatase 4a2
Protein phosphatase Widely expressed in all 
trophoblast lineages 
✓ ✓ (Dong et al., 2012)
Pthlh Parathyroid hormone-
like peptide
Encodes the constitutively expressed 
parathyroid hormone-related peptide 
(PTHrP) 
Constitutively expressed n/a ✓ (Duval et al., 2017, 
Wysolmerski and 
Stewart, 1998)
sFlt-1 Soluble fms related 
receptor tyrosine 
kinase 1
An anti-angiogenic factor that sequesters 
placental growth factor (PGF) and vascular 
endothelial growth factor (VEGF) 
Expressed in the EPC and later 
the Jz
✓ n/a (Breier et al., 1995, 
Kendall and Thomas, 
1993, Levine et al., 
2006)
Transcriptional regulators
Arnt Aryl hydrocarbon 
receptor nuclear 
translocator
Encodes the HIF1 subunit of the 
heterodimeric transcription factor hypoxia 
inducible factor (HIF)
Constitutively expressed ✓ n/a (Adelman et al., 
2000)
Bahd1 Bromo adjacent 
homology domain 
containing 1
Chromatin modifier that mediates 
heterochromatin-associated gene silencing. 
Implicated in the silencing of IGF2 in humans 





Transcriptional co-factor Expressed in all trophoblast 
lineages.
✓ n/a (Dunwoodie et al., 
1998, Withington et 
al., 2006)
Hif1a Hypoxia inducible 
factor 1, alpha subunit
Encodes the HIF1 subunit of the 
heterodimeric transcription factor hypoxia 
inducible factor (HIF)
Constitutively expressed but 
HIF1A protein is degraded in 
normoxia.
✓ n/a (Cowden Dahl et al., 
2005, Kozak et al., 
1997)
miR-126a microRNA 126a Endothelial-specific microRNA Widely expressed in fetal 
endothelium of Lz, 
syncytiotrophoblast, P-TGC, SpT 
and GlyT.
✓ ✓ (Sharma et al., 2019, 
Wang et al., 2008)
Prdm1 PR domain containing Zinc-finger transcriptional repressor Expressed in GlyT progenitors at n/a n/a (Mould et al., 2012)
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sinusoidal TGC; SpA-TGC, spiral artery associated TGC.
1, with ZNF domain E7.5. Highly expressed in SpA-
TGCs.
Tfap2c Transcription factor 
AP-2, gamma
Transcription Factor AP-2 Gamma Expressed in the trophectoderm 
at E4.5. Restricted to Jz and TGCs 
by E11.5.
✓ ✓ (Kuckenberg et al., 
2010)
Sp1 & Sp3 Trans-acting 
transcription factor 1 & 
3
Zinc-finger transcription factors Ubiquitously expressed n/a n/a (Kruger et al., 2007)
Miscellaneous
Cts7 Cathepsin 7 Placenta-specific papain-like cysteine 
cathepsin protease that functions in 
lysosomal proteolysis 
Highly expressed in TGCs at E7.5; 
expression declines and is 
restricted to the Lz by E15.5
✓ n/a (Hemberger et al., 
2000, Deussing et al., 
2002)
Fbxl12 F-box and leucine-rich 
repeat protein 12
Member of the F-box family of proteins, 
which function as the substrate recognition 
component in E3 ubiquitin ligase complexes 
Jz specific at E15.5 n/a ✓ (Nishiyama et al., 
2015, Zheng et al., 
2016, Nakayama and 
Nakayama, 2006)
Pdcd5 Programmed cell death 
5
Promoter of both apoptotic and the non-
apoptotic programmed cell death pathway 
(paraptosis) 
Not reported ✓ ✓ (Wang et al., 2004, 
Liu et al., 1999)




Widely expressed in the EPC and 
Jz; some patchy expression in Lz
✓ n/a (Celebi et al., 2012, 
Reichmann et al., 
2013)
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Table 2:  Genetic mouse models with fetal growth restriction and placentas with reduced glycogen content and/or GlyT phenotypes








markers GlyT localisation Lz phenotype References




 PAS n/a n/a n/a Reduced Lz size (Yang et al., 2003)
Del7AI/+ Ascl2 expressed 
reduced by 40%







(Lefebvre et al., 2009, Oh-
McGinnis et al., 2011)
Ascl2LacZ/Del7AI Ascl2 expressed 
reduced by 60%







(Bogutz et al., 2018)
Bahd1-/- Knockout  (E18.5) n/a 
( 
circumference 
and area at 
E18.5)
 PAS n/a n/a n/a Reduced Lz size (Lakisic et al., 2016)
Csf2-/- Mixed 129/Sv x 
C57BL/6 
background
 (E16.5) Normal (E16.5) n/a  n/a n/a Reduced Lz size (Kanzaki et al., 1991, 
Robertson et al., 1999)






n/a n/a Reduced Lz size; 
vascularisation 
defect
(Yevtodiyenko and Schmidt, 
2006, Appelbe et al., 2013, 
Cleaton et al., 2016)
Egfr-/- Knockout  (from 
E13.5)
 (from E11.5) n/a n/a  Tpbpa 
(E13.5)
n/a n/a (Sibilia and Wagner, 1995)













(Dackor et al., 2009)












 (E11.5) n/a  GlyT:SpT 
ratio
(in 
n/a n/a Increased Lz size (Crossey et al., 2002)
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females)
HtrA1-/- Knockout  (E14.5)  (E14.5) n/a n/a  Tpbpa Mislocalisation 
of Tpbpa+; PAS+ 
cells within Lz
















n/a n/a n/a (Redline et al., 1993, Carter 
et al., 2006, Lopez et al., 
1996, DeChiara et al., 1990)

















(Constância et al., 2005, 
Sferruzzi-Perri et al., 2011, 
Sibley et al., 2004)
LV-hsFLT-1 Over-expression 
of human sFLT-1
 (E18.5)  (E18.5) n/a  GlyT 
proportion 
of Jz
n/a n/a Reduced Lz size (Kuhnel et al., 2017)

















n/a n/a (Lee et al., 2015, Thiaville et 
al., 2013, Kuroiwa et al., 
1996, Relaix et al., 1996, He 
et al., 2016, Curley et al., 



















PAS+ cells to 
decidua








(if dam is 
Pik3ca+/-)









(Foukas et al., 2006, 
Sferruzzi-Perri et al., 2016)
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 Tpbpa Failure of 
Tpbpa+; PAS+ 
cells to migrate 
to decidua 




(Dong et al., 2012)
















(Duval et al., 2017)
Ldoc1-/+ or 
Ldoc1-/-






n/a Normal Pcdh12 
normal
Mislocalisation 
of Prl6a1+ cells 
in Lz
n/a (Naruse et al., 2014)
Sp1+/-;Sp3+/- Embryonic lethal 
between E16.5 
and birth




(Kruger et al., 2007)





n/a Fewer S-TGCs (Celebi et al., 2012, 
Reichmann et al., 2013)





n/a n/a n/a Mislocalisation 




(Kuckenberg et al., 2010, 




















n/a n/a (Sharma et al., 2016)






n/a n/a n/a Reduced Lz size, 
Fewer S-TGCs,
Increased MBS
(Singh et al., 2015)
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 = <20% reduction;  = 20-50% reduction;  = >50% reduction;  = undetected;  = <20% increase;  = 20-50% increase;  = >50% 
increase. Developmental stage in brackets is the time assessed. Total placental glycogen content quantified by biochemical or enzymatic methods 
or estimated from comparison of PAS (Periodic Acid Schiff) staining. E, embryonic day; GlyT, glycogen trophoblast cells; Jz, junctional zone; Lz, 
labyrinth zone; MBS, maternal blood sinusoids; P, postnatal day; n/a, not available; SpT, spongiotrophoblast cells; S-TGCs, sinusoidal trophoblast 
giant cells; Tg, transgenic. * denotes imprinted or X-linked gene; heterozygous inheritance of a null allele from the normally active parental 
lineage effectively ablates gene expression. 
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Table 3: Genetic mouse models with fetal growth restriction and increased placental glycogen content and/or GlyT phenotypes






number GlyT markers GlyT localisation Lz phenotype References
Ascl2-Tg Ascl2 over-
expression













Tpbpa+; PAS+ cells 
within Lz






 (E17.5)  (from E13.5) Normal PAS n/a  Pcdh12+ cell 
area
n/a Fewer S-TGCs (Pennisi et al., 







 (E17.5) n/a   Tpbpa n/a n/a (Sferruzzi-Perri 
et al., 2009)
Esx1-/+ or Esx1-/- Knockout*  (P0)  (E14.5)
 (E18.5)
n/a   Tpbpa n/a Vascularisation 
defect.
Failure of SynT-II 
formation















n/a Increased Jz:Lz 
ratio (no effect 
on gross Lz size)
(Sharma et al., 
2019)
Pcdh12-/- Knockout  (E12.5, 
E17.5)




n/a n/a Mislocalisation 









Knockout*  (E16.5)  (E16.5)  PAS n/a n/a n/a n/a (Cocchia et al., 
2000, Jackman 
et al., 2012)
Phlda2-/+ Knockout* Normal (vs. 
Phlda2+/+ 
littermates)




 glycogen n/a  Tpbpa 
Normal Pcdh12 
Normal Gjb3 
n/a n/a (Frank et al., 
1999, Frank et 
al., 2002, 
Tunster et al., 
2015)






n/a n/a Increased Jz:Lz 
ratio. Impaired 
(Zhang et al., 
2019)
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 = <20% reduction;  = 20-50% reduction;  = >50% reduction;  = <20% increase;  = 20-50% increase;  = >50% increase. 
Developmental stage in brackets is the time assessed. ‡ Total placental glycogen content quantified by biochemical or enzymatic methods or 
estimated from comparison of PAS (Periodic Acid Schiff) staining. E, embryonic day; GlyT, glycogen trophoblast cells; Lz, labyrinth zone; P, 
postnatal day; n/a, not available; S-TGCs, sinusoidal trophoblast giant cells; SynT-II, syncytiotrophoblast cell layer II; Tg, transgenic. * denotes 
imprinted or X-linked gene; heterozygous inheritance of a null allele from the normally active parental lineage effectively ablates gene 
expression.
only) remodelling of 
maternal spiral 
arteries.
Pthlh-/- Knockout  (from 
E16.5)








(Duval et al., 
2017)
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content‡ GlyT number GlyT markers GlyT localisation Lz phenotype References
Cdkn1c-/+ Knockout*  (E15.5, 
E18.5)
= (P0)







n/a Increased Lz cell 
number, 
Fewer S-TGCs
(Georgiades et al., 
2002, Coan et al., 
2006, Tunster et al., 
2011, Takahashi et 
al., 2000)
Cts7 Tg Cts7 over-
expression
n/a n/a n/a  (E12.5)  Tpbpa (E10.5, 
E12.5)
n/a Fewer S-TGCs (Hemberger et al., 












 PAS   Tpbpa
 Pcdh12
n/a  Gcm1 
 Dlx3 
(Dackor et al., 2007, 
Dackor et al., 
2009b)






 (E15.5) n/a n/a n/a (Leighton et al., 
1995, Esquiliano et 
al., 2009)
Pgf-/- Knockout Normal 
(P0)
 (P0)  glycogen
 Best’s 
Carmine staining
 n/a n/a Reduced Lz size (Achen et al., 1997, 
Tayade et al., 2007, 
Parchem et al., 
2018)
 = <20% reduction;  = 20-50% reduction;  = >50% reduction;  = <20% increase;  = 20-50% increase;  = >50% increase. 
Developmental stage in brackets is the time assessed. ‡ Total placental glycogen content quantified by biochemical or enzymatic methods or 
estimated from comparison of PAS (Periodic Acid Schiff) staining. E, embryonic day; GlyT, glycogen trophoblast cells; Lz, labyrinth zone; P, 
postnatal day; n/a, not available; S-TGCs, sinusoidal trophoblast giant cells; Tg, transgenic. * denotes imprinted or X-linked gene; heterozygous 
inheritance of a null allele from the normally active parental lineage effectively ablates gene expression. 
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Table 5: Genetic mouse models with glycogen content or GlyT phenotypes associated with embryonic lethality at mid-gestation
Mouse 
model






content‡ GlyT number GlyT markers
GlyT 
localisation Lz phenotype References
Arnt-/- Knockout  By E10.5 n/a n/a  
progenitors 
(E9.5)




(Adelman et al., 2000, Kozak et 
al., 1997, Maltepe et al., 1997, 
Watson and Cross, 2005)
Ascl2-/- or
Ascl2-/+
Knockout* By E10.5 n/a n/a  
progenitors 
(E8.5)
 Tpbpa (E8.5) n/a Vascularisation defect (Guillemot et al., 1995, 







By E13.5  (E12.5) n/a  Migratory 
GlyT
 Tpbpa Impaired 
migration to 
decidua
Vascularisation defect (Dunwoodie et al., 1998, 
Withington et al., 2006, Yin et 







By E12.5  
(incomplete 
penetrance)
 glycogen   Tpbpa 
 PAS 
n/a Disrupted structure, 
Vascularisation defect






(e.g., NTD, heart 
defects) 
By E10.5 n/a n/a  
progenitors 
 Tpbpa n/a Impaired 
vascularisation of 
chorion
(Cowden Dahl et al., 2005, 








By E13.5 n/a  PAS 
(E13.5)
 (E13.5) n/a n/a Disorganised structure,
Necrotic and 
haemorrhagic
(Li et al., 2017)
Peg10+/- Knockout* By E10.5 n/a n/a  
progenitors 
(E9.5)
 Tpbpa (E9.5) n/a Impaired development (Ono et al., 2006)
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By E10.5 n/a n/a n/a Normal Tpbpa Failure to 
migrate to 
decidua
Disrupted structure (Mould et al., 2012, Vincent et 
al., 2005)
 = <20% reduction;  = 20-50% reduction;  = >50% reduction;  = undetected; Developmental stage in brackets is the time assessed. 
‡ Total placental glycogen content quantified by biochemical or enzymatic methods or estimated from comparison of PAS (Periodic Acid Schiff) 
staining.  E, embryonic day; GlyT, glycogen trophoblast cells; Lz, labyrinth zone; n/a, not available; * denotes imprinted or X-linked gene; 
heterozygous inheritance of a null allele from the normally active parental lineage effectively ablates gene expression. 
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